IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New inhaled drug AGMB-447 tested for lung scarring disease
Disease control CompletedThis study tests an inhaled drug called AGMB-447 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. The main goal is to check safety and how the body processes the drug. 143 participants will receive either the drug or a pla…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Agomab Spain S.L. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug MN-001 tested for scarred lungs in tiny trial
Disease control CompletedThis study tested an experimental drug called MN-001 (tipelukast) in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants took either the drug or a placebo twice daily for six months, then everyone could take the drug for an…
Matched conditions: IPF
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental drug PMG1015 tested for lung scarring disease
Disease control CompletedThis early-phase trial tested an experimental drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal was to check the drug's safety and how the body processes it, not whether it works. Participants received either PMG1015…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Pulmongene Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill shows promise in slowing lung scarring disease
Disease control CompletedThis study tested an oral drug called GRI-0621 in 35 adults with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. Participants took either the drug or a placebo daily for 12 weeks. The main goals were to check safety and m…
Matched conditions: IPF
Phase: PHASE2 • Sponsor: GRI Bio Operations, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New antibody for lung scarring passes first safety check in healthy volunteers
Disease control CompletedThis study tested a single dose of HLX6018, an experimental antibody, in 66 healthy adults to see if it is safe and how the body handles it. HLX6018 is designed to block a protein pathway involved in idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Because thi…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC
-
Simple questionnaire could bring palliative care home for lung disease patients
Knowledge-focused CompletedThis study tested a simple questionnaire to help match newly diagnosed idiopathic pulmonary fibrosis (IPF) patients to the right level of palliative care. Researchers asked 30 patients a few questions to see if the tool could predict their needs as accurately as a doctor's judgme…
Matched conditions: IPF
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Doctors test which score best predicts lung disease survival
Knowledge-focused CompletedThis completed study looked at 143 people with two types of lung scarring diseases (IPF and hypersensitivity pneumonitis). Researchers compared three different scoring systems (GAP, ILD-GAP, and CPI) to see which one best predicts how long patients might live. The goal was to fin…
Matched conditions: IPF
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:07 UTC